TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules
Study: NCT03493347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equine-assisted Occupational Therapy
Description: Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
Study: NCT03499171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Description: Citalopram is taken once a day as an add-on to PPI treatment (2x/d).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo is taken once a day as an add-on to PPI treatment (2x/d)
Study: NCT01165385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60, 75 or 100 mg/m2 , day 1 - 3 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 400 mg, 600 mg or 800 mg/day, daily
Study: NCT02119676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth
Study: NCT02543554

Intervention type: PROCEDURE
Intervention: lung protective ventilation
Description: Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
Study: NCT02712086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein supplementation
Description: Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
Study: NCT00401089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng
Description: The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Panax Ginseng
Description: The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
Study: NCT03700944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
Study: NCT02254174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol
Description: Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent® Diskus®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva®
Study: NCT01196260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine and Oxaliplatin
Description: Capecitabine and Oxaliplatin will be under the NSCLC guideline
Study: NCT02149745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Calling the patient's name
Description: calling the patient's name during anesthesia reversal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Not calling the patient's name
Description: giving verbal stimulus other than the patient's name during anesthesia reversal
Study: NCT03257722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
Study: NCT01311245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-tailored intervention
Description: Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-stage-tailored Intervention
Description: Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
Study: NCT03502161

Intervention type: DEVICE
Intervention: QuantiFERON CMV Assay
Description: Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
Study: NCT03748953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib Capsules
Study: NCT03539003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
Study: NCT02841878

Intervention type: GENETIC
Group type: OTHER
Intervention: Analysis on colorectal biopsy
Study: NCT03588962

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: In-stent restenosis
Description: Patch tests for the metals applicated in each of the patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: In-stent restenosis
Description: Patch tests for the metals applicated in each of the patients
Study: NCT01662648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
Study: NCT02905734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Single administration of an active treatment (nicotine patch)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: Single administration of a placebo treatment
Study: NCT02773966

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Kypho-IORT
Description: During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: EBRT
Description: The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
Study: NCT00953394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous 5 fluouracil infusion plus long-acting octreotide
Description: long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
Study: NCT00755079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release beta-2 adrenergic agonist
Description: Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
Study: NCT00630045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy with oxaliplatin and capecitabine
Description: oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of liver metastasis
Description: surgery with the aim of R0 resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of liver metastasis
Description: surgery with the aim of R0 resection
Study: NCT03527576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.0308 MEQ/ML Injectable Solution
Description: Intravenous injection of NaCl 0.9% before the surgery.
Study: NCT00899652

Intervention type: GENETIC
Intervention: Southern blotting

Intervention type: GENETIC
Intervention: chromosomal translocation analysis

Intervention type: GENETIC
Intervention: cytogenetic analysis

Intervention type: GENETIC
Intervention: gene rearrangement analysis

Intervention type: GENETIC
Intervention: mutation analysis
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
Study: NCT01850927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischaemic preconditioning

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Study: NCT04054947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suicide Prevention Program
Description: Structured care management to improve adherence to discharge planning.
Study: NCT03067233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
Study: NCT01337102

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physician Receives QoL results
Description: Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physician Does not receive the results
Description: Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
Study: NCT03570463

Intervention type: BEHAVIORAL
Intervention: GLA:D Back
Description: The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
Study: NCT04643600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine, 500 Mg Oral Capsule
Description: The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine, 500 Mg Oral Capsule
Description: The strength test of the the quadriceps muscle, will be measured in all patients on the Biodex isokinetic device. Quadriceps strength testing will be performed on 2 occasions. On one occasion without medication, except those that the patient may take permanently, and on the other 90 minutes after the patient takes 1 tbl of L - Arginine 500 mg on mouth to an empty stomach ,in order to monitor the possible increase in quadriceps strength.
Study: NCT01227629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran with ASA
Description: dose comparison in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran without ASA
Description: dose comparison

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran without ASA
Description: dose comparison

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran without ASA
Description: dose comparison
Study: NCT04176601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage coaching
Description: Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. All sessions are provided via phone or videocall (Zoom). The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first-action planning (a derivative of problem solving therapy)-and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands.
Study: NCT03753581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Care protocol plus microcurrents
Description: CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Care protocol plus placebo microcurrents
Description: The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
Study: NCT03539003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
Study: NCT00904553

Intervention type: RADIATION
Intervention: Novalis Shaped Beam Surgery
Description: Treatment using Novalis SRS
Study: NCT00162474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Study: NCT01674166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: single dose 0.03 mg/kg prucalopride open label
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3577
Description: MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
Study: NCT01846585

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Arousal Based Therapy for Insomnia
Description: Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
Study: NCT02273622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hydroxytyrosol
Description: Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hydroxytyrosol
Description: Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo